PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of Parkinson’s Disease
May 17, 2021 07:59 ET
|
PharmaTher Holdings Ltd.
TORONTO, May 17, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a psychedelics biotech company, is pleased to announce that the U.S....
PharmaTher Expands Patent Portfolio with Filing of U.S. Patent Application for Ketamine and Repurposing of Psychedelics with panaceAI™
April 27, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, April 27, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, today announced that...
PharmaTher Announces Submission of IND Application with the FDA for Phase 2 Clinical Trial Evaluating Ketamine in the Treatment of Parkinson’s Disease
April 20, 2021 07:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, April 20, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, today announced it...
PharmaTher Provides Update on Psychedelic Product Programs
April 15, 2021 09:00 ET
|
PharmaTher Holdings Ltd.
TORONTO, April 15, 2021 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM) (OTCQB: PHRRF), a specialty psychedelic pharmaceutical company, is pleased to provide...
Newscope Announces Name Change to PharmaTher Holdings Ltd.
April 13, 2021 11:29 ET
|
Newscope Capital Corporation
TORONTO, April 13, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that, further to the news release dated April 8, 2021, its...
Newscope Announces Name Change
April 08, 2021 10:40 ET
|
Newscope Capital Corporation
TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) is pleased to announce that it has filed an alteration notice with BC Registry...
Newscope Capital Provides Dial-In Information for Special Meeting
April 01, 2021 14:01 ET
|
Newscope Capital Corporation
TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company”) (CSE: PHRM) (OTCQB: PHRRF) would like to provide the following dial-in information for the Company’s upcoming...
World Leading Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor
March 16, 2021 09:15 ET
|
Newscope Capital Corporation
TORONTO, March 16, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc....
PharmaTher Expands to Neuromuscular Diseases with Exclusive License Agreement for Ketamine in the Treatment of Lou Gehrig’s Disease
March 02, 2021 07:00 ET
|
Newscope Capital Corporation
TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life...
Newscope Announces DTC Eligibility of Its Common Shares in the United States
March 01, 2021 07:57 ET
|
Newscope Capital Corporation
TORONTO, March 01, 2021 (GLOBE NEWSWIRE) -- Newscope Capital Corporation (the “Company” or “Newscope”) (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc....